Lessigiarska Iglika, Nankov Atanas, Bocheva Adriana, Pajeva Ilza, Bijev Atanas
Centre of Biomedical Engineering, Bulgarian Academy of Sciences, Bulgaria.
Farmaco. 2005 Mar;60(3):209-18. doi: 10.1016/j.farmac.2004.11.008.
The present study focuses on development of new potential inhibitors of cyclooxygenase-2 (COX-2): series of N-pyrrolylcarboxylic acids. 3D-QSAR (Quantitative Structure-Activity Relationship) CoMFA (Comparative Molecular Field Analysis) and CoMSIA (Comparative Molecular Similarity Index Analysis) models for predicting inhibitory activities against COX-1 and COX-2 as well as for evaluating in vivo anti-inflammatory activity were obtained and used for preliminary screening of new anti-inflammatory N-pyrrolylcarboxylic acids. Nine compounds were selected for in vivo testing and evaluated for their potency to decrease carrageenin-induced edema in rats. The compounds were applied i.p. at doses 20 mg/kg and 40 mg/kg and p.o. at doses 10 mg/kg and 40 mg/kg. Six compounds showed more than 70% protection of the edema. Indomethacin (2 mg/kg i.p.), used as a reference drug, possessed 54% anti-inflammatory activity under similar experimental conditions.
本研究聚焦于新型环氧化酶-2(COX-2)潜在抑制剂的开发:一系列N-吡咯基羧酸。获得了用于预测对COX-1和COX-2抑制活性以及评估体内抗炎活性的3D-QSAR(定量构效关系)CoMFA(比较分子场分析)和CoMSIA(比较分子相似性指数分析)模型,并将其用于新型抗炎N-吡咯基羧酸的初步筛选。选择了9种化合物进行体内测试,并评估它们减轻角叉菜胶诱导的大鼠水肿的效力。化合物分别以20mg/kg和40mg/kg的剂量腹腔注射以及10mg/kg和40mg/kg的剂量口服给药。6种化合物对水肿的保护作用超过70%。作为参比药物的吲哚美辛(2mg/kg腹腔注射)在类似实验条件下具有54%的抗炎活性。